Belkisyolé Alarcón de Noya

Belkisyolé Alarcón de Noya

Auto-generated profile, based on publicly available information

Belkisyolé Alarcón de Noya

Sección de Inmunología, Instituto de Medicina Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas 1050, Venezuela

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Acta Tropica
Verified
Journal Article
Closed access
ZDZoraida Díaz-Bello
Zoraida Díaz-Bello
BNBelkisyolé Alarcón de Noya
Belkisyolé Alarcón de Noya
AMArturo Muñoz-Calderón
Arturo Muñoz-Calderón
RRRaiza Ruiz-Guevara
Raiza Ruiz-Guevara
LMLuciano Mauriello
Luciano Mauriello
ONOscar Noya-González
Oscar Noya-González

1 September 2021 in Acta Tropica
Verified
Journal Article
Open access
JPJulio Alonso Padilla
Julio Alonso Padilla
MLManuel Carlos López
Manuel Carlos López
MEMónica Esteva
Mónica Esteva
MZMaan Zrein
Maan Zrein
ACAina Casellas
Aina Casellas
RVRodolfo Viotti
Rodolfo Viotti
Chagas disease, caused by the protozoan Trypanosoma cruzi, affects more than 6 million people worldwide. Following a mostly asymptomatic acute phase, the disease progresses to a long-lasting chronic phase throughout which life-threatening disorders to the heart and/or gastrointestinal tract will manifest in about 30% of those chronically infected. During the chronic phase, the parasitemia is low and intermittent, while a high level of anti-T. cruzi antibodies persist for years. These two features hamper post-chemotherapeutic follow-up of patients with the tools available. The lack of biomarkers for timely assessment of therapeutic response discourages a greater use of the two available anti-parasitic drugs, and complicates the evaluation of new drugs in clinical trials. Herein, we investigated in a blinded case-control study the serological reactivity over time of a group of parasite-derived antigens to potentially address follow up of T. cruzi chronically infected subjects after treatment. We tested PFR2, KMP11, HSP70, 3973, F29 and the InfYnity multiplexed antigenic array, by means of serological assays on a multi-national retrospective collection of samples. Some of the antigens exhibited promising results, underscoring the need for further studies to determine their potential role as treatment response biomarkers.

10 March 2022 in Experimental Parasitology
Verified
Journal Article
Closed access
GSGabriela Sánchez
Gabriela Sánchez
ESEva Salazar-Alcalá
Eva Salazar-Alcalá
FHFernando Hernández
Fernando Hernández
PDPierre-Antoine Deglesne
Pierre-Antoine Deglesne
ZBZoraida Díaz Bello
Zoraida Díaz Bello
MMMercedes Fernandez Mestre
Mercedes Fernandez Mestre

24 May 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EEEdwin Eliel Escobar-Guevara
Edwin Eliel Escobar-Guevara
MQMaría Esther de Quesada-Martínez
María Esther de Quesada-Martínez
YRYhajaira Beatriz Roldán-Dávila
Yhajaira Beatriz Roldán-Dávila
BNBelkisyolé Alarcón de Noya
Belkisyolé Alarcón de Noya
MAMiguel Antonio Alfonzo-Díaz
Miguel Antonio Alfonzo-Díaz
Human immunodeficiency virus-1 (HIV-1) and Toxoplasma gondii can invade the central nervous system and affect its functionality. Advanced HIV-1 infection has been associated with defects in immune response to T. gondii, leading to reactivation of latent infections and development of toxoplasmic encephalitis. This study evaluates relationship between changes in immune response to T. gondii and neurocognitive impairment in HIV-1/T. gondii co-infected patients, across different stages of HIV-1 infection. The study assessed the immune response to T. gondii by measuring cytokine production in response to parasite antigens, and also neurocognitive functions by performing auditory and visual P300 cognitive evoked potentials, short term memory (Sternberg) and executive function tasks (Wisconsin Card Sorting Test-WCST) in 4 groups of individuals: HIV-1/T. gondii co-infected (P2), HIV-1-infected/T. gondii-non-infected (P1), HIV-1-non-infected/T. gondii-infected (C2) and HIV-1-non-infected/T. gondii-non-infected (C1). Patients (P1 and P2) were grouped in early/asymptomatic (P1A and P2A) or late/symptomatic (P1B/C and P2B/C) according to peripheral blood CD4+ T lymphocyte counts (>350 or <350/μL, respectively). Groups were compared using T-student or U-Mann-Whitney tests as appropriate, p<0.05 was considered as significantly. For P300 waves, HIV-1-infected patients (P1) had significantly longer latencies and significantly smaller amplitudes than uninfected controls, but HIV-1/T. gondii co-infected patients (P2) had significantly longer latencies and smaller amplitude than P1. P1 patients had significantly poorer results than uninfected controls in Sternberg and WCST, but P2 had significantly worse results than P1. HIV-1 infection was associated with significantly lower production of IL-2, TNF-α and IFN-γ in response to T. gondii from early/asymptomatic stages, when comparing P2 patients to C2 controls. These findings may indicate impairment in anti-parasitic response in co-infected patients, facilitating early limited reactivation of the parasitic latent infection, therefore creating cumulative damage in the brain and affecting neurocognitive functions from asymptomatic stages of HIV-1 infection, as suggested by defects in co-infected patients in this study.

8 August 2020
Verified
Journal Article
Closed access
BNBelkisyolé Alarcón de Noya
Belkisyolé Alarcón de Noya
RGRaiza Ruiz Guevara
Raiza Ruiz Guevara
En este artículo se revisan las infecciones parasitarias de mayor impacto a la gestante en el trópico latinoamericano, con repercusiones para la madre y el niño. Algunas de estas afecciones se deben tomar en cuenta para el diseño de medidas preventivas de la población en general, ya que aquellas debilitan el estado general de la gestante y también pueden tener un efecto directo sobre la placenta y afectar al feto ”. Las mujeres tienen, por tanto, una morbilidad añadida derivada del embarazo y el parto, con una cifra estimada en 2017, de unos 80 millones de casos relacionados con más de 800.000 años vividos con discapacidad. En paralelo, 16 infecciones parasitarias causan casi un millón de muertes, 3 millones de casos y 96 millones de años de vida ajustados por discapacidad, AVAD, anualmente. De estos 16 parásitos, 5 pueden transmitirse verticalmente al feto (malaria, toxoplasmosis, enfermedad de Chagas, leishmaniasis visceral y tripanosomiasis africana) o durante el parto (tricomoniasis). Los 10 restantes (protozoos intestinales y helmintos) pueden debilitar a la madre con consecuencias de diversa intensidad para el feto (anemia, bajo peso al nacer, mortinatos). En los trópicos, también existen condiciones especiales que agravan este cuadro nocivo durante el embarazo

1 January 2015
Verified
Book Chapter
Closed access
PDF file
ZBZoraida Díaz Bello
Zoraida Díaz Bello
BNBelkisyolé Alarcón de Noya
Belkisyolé Alarcón de Noya